{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:10:27Z","timestamp":1787861427263,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101711","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T04:57:27Z","timestamp":1665550647000},"page":"101711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists"],"prefix":"10.1016","volume":"36","author":[{"given":"Philippe","family":"Chanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101711_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas:The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2022.101711_bib2","series-title":"The pituitary","first-page":"495","article-title":"Prolactinoma","author":"Chanson","year":"2022"},{"issue":"3","key":"10.1016\/j.beem.2022.101711_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra1801490","article-title":"Psychotic disorders","volume":"379","author":"Lieberman","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101711_bib4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatr"},{"issue":"2","key":"10.1016\/j.beem.2022.101711_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11102-008-0106-6","article-title":"Drugs and prolactin","volume":"11","author":"Molitch","year":"2008","journal-title":"Pituitary"},{"issue":"2 Suppl","key":"10.1016\/j.beem.2022.101711_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A\u00a0review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"issue":"7","key":"10.1016\/j.beem.2022.101711_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/11533140-000000000-00000","article-title":"Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management","volume":"24","author":"Coker","year":"2010","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.beem.2022.101711_bib8","first-page":"853","article-title":"Antidepressant use and circulating prolactin levels","volume":"27","author":"Reeves","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.beem.2022.101711_bib9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/11595660-000000000-00000","article-title":"Serotonin reuptake inhibitors and hyperprolactinaemia: a case\/non-case study in the French pharmacovigilance database","volume":"34","author":"Trenque","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.beem.2022.101711_bib10","first-page":"55","article-title":"Prolactin assays and regulation of secretion: animal and human data","author":"Binart","year":"2019"},{"issue":"2","key":"10.1016\/j.beem.2022.101711_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt","year":"2011","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"10.1016\/j.beem.2022.101711_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"Am J Psychiatr"},{"issue":"12","key":"10.1016\/j.beem.2022.101711_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.beem.2022.101711_bib14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin Therapeut"},{"issue":"4","key":"10.1016\/j.beem.2022.101711_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2265.1998.00569.x","article-title":"Serum prolactin concentration in patients taking neuroleptic drugs","volume":"49","author":"Pollock","year":"1998","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7332","key":"10.1016\/j.beem.2022.101711_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","article-title":"Hyperprolactinaemia caused by antipsychotic drugs","volume":"324","author":"Wieck","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2022.101711_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review","volume":"182","author":"Wieck","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"11","key":"10.1016\/j.beem.2022.101711_bib18","first-page":"1238","article-title":"Sexual side effects of antipsychotic medication: evaluation and interventions","volume":"41","author":"Sullivan","year":"1990","journal-title":"Hosp Community Psychiatry"},{"issue":"2","key":"10.1016\/j.beem.2022.101711_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","article-title":"The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis","volume":"22","author":"Smith","year":"2002","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.beem.2022.101711_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1976.tb01953.x","article-title":"Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups","volume":"5","author":"Rivera","year":"1976","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"8","key":"10.1016\/j.beem.2022.101711_bib21","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.beem.2022.101711_bib22","doi-asserted-by":"crossref","first-page":"209 e1","DOI":"10.1016\/j.genhosppsych.2011.07.004","article-title":"The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis","volume":"34","author":"Broekhof","year":"2012","journal-title":"Gen Hosp Psychiatr"},{"issue":"1","key":"10.1016\/j.beem.2022.101711_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/PL00007539","article-title":"Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder","volume":"250","author":"Melkersson","year":"2000","journal-title":"Eur Arch Psychiatr Clin Neurosci"},{"issue":"5","key":"10.1016\/j.beem.2022.101711_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00006842-200009000-00018","article-title":"Effect of risperidone on prolactinoma growth in a psychotic woman","volume":"62","author":"Pal","year":"2000","journal-title":"Psychosom Med"},{"issue":"4","key":"10.1016\/j.beem.2022.101711_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0163-8343(85)90053-2","article-title":"The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report","volume":"7","author":"Weingarten","year":"1985","journal-title":"Gen Hosp Psychiatr"},{"issue":"4","key":"10.1016\/j.beem.2022.101711_bib26","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1176\/appi.neuropsych.11110348","article-title":"Cabergoline-induced psychosis in a patient with undiagnosed depression","volume":"24","author":"Bilal","year":"2012","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.beem.2022.101711_bib27","article-title":"Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania","volume":"2015","author":"Burback","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"6","key":"10.1016\/j.beem.2022.101711_bib28","first-page":"252","article-title":"Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia","volume":"43","author":"Frye","year":"1982","journal-title":"J\u00a0Clin Psychiatr"},{"issue":"3","key":"10.1016\/j.beem.2022.101711_bib29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4103\/0253-7176.207314","article-title":"Cabergoline-induced mania in a patient of pituitary microadenoma","volume":"39","author":"Mohapatra","year":"2017","journal-title":"Indian J Psychol Med"},{"key":"10.1016\/j.beem.2022.101711_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2010.3185","article-title":"Treating prolactinoma and psychosis: medication and cognitive behavioural therapy","volume":"2011","author":"Nieman","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"9","key":"10.1016\/j.beem.2022.101711_bib31","first-page":"700","article-title":"Bromocriptine-induced schizophrenia","volume":"85","author":"Peter","year":"1993","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"7","key":"10.1016\/j.beem.2022.101711_bib32","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2022.101711_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1037\/a0033448","article-title":"Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients","volume":"21","author":"Kalkavoura","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.beem.2022.101711_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","article-title":"Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study","volume":"65","author":"Cavallaro","year":"2004","journal-title":"J\u00a0Clin Psychiatr"},{"issue":"4","key":"10.1016\/j.beem.2022.101711_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000118184","article-title":"Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment","volume":"13","author":"Cohn","year":"1985","journal-title":"Neuropsychobiology"},{"issue":"11","key":"10.1016\/j.beem.2022.101711_bib36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03345068","article-title":"Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders","volume":"23","author":"Tollin","year":"2000","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.beem.2022.101711_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.genhosppsych.2007.11.002","article-title":"Cabergoline-induced psychotic exacerbation in schizophrenic patients","volume":"30","author":"Chang","year":"2008","journal-title":"Gen Hosp Psychiatr"},{"issue":"8","key":"10.1016\/j.beem.2022.101711_bib38","first-page":"737","article-title":"Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine?","volume":"37","author":"Smith","year":"1992","journal-title":"J\u00a0Reprod Med"},{"issue":"2","key":"10.1016\/j.beem.2022.101711_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/EJE-20-0125","article-title":"Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma","volume":"183","author":"Allard","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101711_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0033-3182(10)70718-0","article-title":"Management of psychosis associated with a prolactinoma: case report and review of the literature","volume":"51","author":"Ali","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.beem.2022.101711_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/573252","article-title":"New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature","volume":"2010","author":"Santos Andrade","year":"2010","journal-title":"Case Rep Med"},{"issue":"3","key":"10.1016\/j.beem.2022.101711_bib42","doi-asserted-by":"crossref","first-page":"C11","DOI":"10.1530\/EJE-20-0607","article-title":"Dopamine agonists and antipsychotics","volume":"183","author":"Molitch","year":"2020","journal-title":"Eur J Endocrinol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:25Z","timestamp":1761497905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22000987"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101711","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101711"}}